Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: J Invest Dermatol. 2019 Jan 29;139(7):1439–1448. doi: 10.1016/j.jid.2018.11.035

Figure 3. Loss of primary cilia potentiates Ras/MAPK pathway activation.

Figure 3.

(a) GSEA for HH pathway activation in RNA-sequencing datas obtained from ASZ_PA upon DMSO (control) versus CBD (10μM) treatment.

(b) GSEA for Ras pathway activation in RNA-sequencing datas obtained from ASZ_PA or ASZ_ERRasV12/Dox-4OHT upon DMSO (control) versus CBD (10μM) treatment.

(c) Western blot for p-ERK1/2 (as readout for Ras/MAPK pathway activation), total ERK1/2 and β tubulin (loading control) in ASZ_ERRasV12 and UWBCC_ERRasV12 upon doxycycline/4OHT and DMSO (control) versus CBD treatment.

(d) p-MEK immunostaining (as readout for Ras/MAPK pathway activation) in ASZ_ERRasV12 and UWBCC_ERRasV12 upon doxycycline/4OHT and DMSO (control) versus CBD treatment.

(e) Quantification of p-MEK immunostaining in ASZ_ERRasV12 and UWBCC_ERRasV12 upon doxycycline/4OHT and DMSO (control) versus CBD treatment.

(f) Western blot for p-ERK1/2, total ERK1/2 and β tubulin (loading control) in ASZ_ERRasV12 and UWBCC_ERRasV12 upon doxycycline/4OHT after transfection with ns_siRNA versus OFD1_siRNA.

Scale bars indicate 25μm. Horizontal and error bars in (e) represent the mean ± SD. *p < 0.05, **p < 0.01 ***p < 0.001.